Amblyopia, often called "lazy eye," is a condition causing poor vision in one eye. It affects 1% to 5% of kids and young adults. This can be due to issues like uncorrected vision differences between eyes (anisometropia) or eye misalignment (strabismus). Besides poor vision, people with amblyopia might struggle with focusing, depth perception, and reading. Luminopia is a new treatment approved by the FDA that uses a special way to help both eyes work together. Since its release in November 2022, many patients have started using it. This study collects data from those using Luminopia to learn more about its effects. To join, you need a diagnosis of amblyopia and must have used Luminopia for at least 12 weeks. You cannot join if you've been in other Luminopia studies.

• The study involves collecting data from patients who have used Luminopia for at least 12 weeks.
• Participants must not have been in any previous Luminopia trials.
• Information gathered will help doctors understand how well Luminopia works in real life.